Clinical TrialsPositive topline data from initial proof of concept human trial in pancreatic cancer pain.
Market StrategyAMIX is prioritizing pancreatic cancer pain due to the significant unmet need, potential to conserve capital, and an accelerated path to market.
Technology InnovationAMIX's breakthrough platform technology could transform the field of electrophysiology by detecting neural signals that indicate pain or disease and destroying those nerves at the source.